Niches and Nanoparticles for Local and Systemic Immune Modulation
09 November 2016 12:00 to 13:00 EST
220 Mass. Avenue, Cambridge MA - USA
Speaker: Lonnie Shea, PhD William and Valerie Hall Chair and Professor Department of Biomedical Engineering, University of Michigan
Seminar Abstract: Aberrant immune responses are implicated in disease progression, and diagnostic and therapeutic strategies are being developed based on the aberrant responses or through modulating the responses. My laboratory has been working to establish synthetic niches to locally modulate tissue growth for cancer and diabetes therapies. Furthermore, we have developed nanoparticles as a means to attenuate antigen specific immune responses in autoimmune disease and allogeneic cell transplantation.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Speaker | Lonnie Shea, PhD
Lonnie Shea received his PhD with Jennifer Linderman in chemical engineering and scientific computing from Michigan in 1997 and was a postdoctoral fellow with David Mooney at the U-M Dental School. After 15 years on the faculty at Northwestern University’s Department of Chemical and Biological Engineering, Shea moved to the University of Michigan as chair of the Department of Biomedical Engineering. His laboratory has been at the interface of regenerative medicine, drug and gene delivery, and immune tolerance. Technologies developed in his lab have been applied to ovarian follicle maturation for treating infertility, islet transplantation for diabetes therapies, nerve regeneration for treating paralysis, autoimmune diseases and allogeneic cell transplantation, and cancer diagnostics. He is also developing and applying systems biology approaches to molecularly dissect tissue formation and identify key drivers of normal and abnormal growth. Shea has published more than 200 manuscripts, He served as director of an NIH Biotechnology Training Grant, and is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), a standing member of the Biomaterials and Biointerfaces study section at NIH, and a member of the editorial boards for several journals.